Opus Genetics (IRD) Change in Accured Expenses (2010 - 2026)
Opus Genetics (IRD) posted quarterly Change in Accured Expenses of $432000.0 for Q1 2026, up 58.82% year-over-year from $272000.0 in Q1 2025, and up 149.48% quarter-over-quarter from -$873000.0 in Q4 2025.
Powered by 
Analysis
Opus Genetics (IRD) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has reported Change in Accured Expenses for 17 consecutive years, with $432000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 58.82% year-over-year to $432000.0; the TTM figure through Mar 2026 stood at -$3.3 million (down 179.08% YoY), while the FY2025 annual figure was -$3.5 million, down 161.59% from the prior year.
- Change in Accured Expenses climbed to $432000.0 in Q1 2026 per IRD's latest filing, from -$873000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.4 million in Q4 2024 and bottomed at -$1.9 million in Q2 2025.
- Historically, Change in Accured Expenses has averaged $157882.4 across 5 years, with a median of $1000.0 in 2022.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses jumped 149700.0% — and 2025, when it slumped 1109.94%.
- Opus Genetics' Change in Accured Expenses stood at $461000.0 in 2022, then slumped by 125.16% to -$116000.0 in 2023, then jumped by 2129.31% to $2.4 million in 2024, then sank by 137.09% to -$873000.0 in 2025, then jumped by 149.48% to $432000.0 in 2026.
- Business Quant data shows IRD's Change in Accured Expenses at $432000.0 in Q1 2026, -$873000.0 in Q4 2025, and -$946000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Opus Genetics | 446.86 Mn | 358.05 Mn | - | 804,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 804,000.00 |
| Mar 31, 2026 | 432,000.00 |
| Dec 31, 2025 | -873,000.00 |
| Sep 30, 2025 | -946,000.00 |
| Jun 30, 2025 | -1.95 Mn |
| Mar 31, 2025 | 272,000.00 |
| Dec 31, 2024 | 2.35 Mn |
| Sep 30, 2024 | 1.75 Mn |
| Jun 30, 2024 | -161,000.00 |
| Mar 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | -116,000.00 |
| Sep 30, 2023 | -1.51 Mn |
| Jun 30, 2023 | 1.50 Mn |
| Mar 31, 2023 | 247,000.00 |
| Dec 31, 2022 | 461,000.00 |
| Sep 30, 2022 | -194,000.00 |
| Jun 30, 2022 | 1,000.00 |
| Mar 31, 2022 | -319,000.00 |
| Dec 31, 2021 | 612,000.00 |
| Sep 30, 2021 | 49,000.00 |